Sotera Health (NASDAQ:SHC) Updates FY 2025 Earnings Guidance

Sotera Health (NASDAQ:SHC) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.810-0.860 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Sotera Health Stock Up 2.1%

Shares of Sotera Health stock traded up $0.33 during trading on Thursday, hitting $16.14. 181,082 shares of the stock were exchanged, compared to its average volume of 1,388,142. The firm’s 50-day moving average price is $16.12 and its 200 day moving average price is $13.71. Sotera Health has a 12-month low of $9.53 and a 12-month high of $17.78. The company has a debt-to-equity ratio of 3.87, a current ratio of 2.38 and a quick ratio of 2.23. The stock has a market cap of $4.58 billion, a price-to-earnings ratio of 84.96 and a beta of 1.82.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Friday, August 8th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.03. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. The business had revenue of $294.34 million during the quarter, compared to analysts’ expectations of $275.81 million. During the same period in the prior year, the company earned $0.19 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. As a group, analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on SHC shares. Wall Street Zen upgraded shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Weiss Ratings restated a “sell (d+)” rating on shares of Sotera Health in a report on Friday, October 31st. Barclays upped their price objective on shares of Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Sotera Health from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Piper Sandler increased their price objective on shares of Sotera Health from $15.00 to $17.00 and gave the stock a “neutral” rating in a report on Wednesday. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.40.

Insider Activity at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $120,880,000.00. Following the sale, the director directly owned 41,215,301 shares of the company’s stock, valued at approximately $622,763,198.11. This represents a 16.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Pincus & Co. Warburg sold 12,000,000 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $181,320,000.00. Following the completion of the sale, the director directly owned 61,822,952 shares in the company, valued at approximately $934,144,804.72. This represents a 16.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,126,611 shares of company stock worth $304,273,888 over the last ninety days. 47.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its holdings in Sotera Health by 831.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock valued at $37,000 after buying an additional 2,935 shares in the last quarter. Vident Advisory LLC lifted its stake in shares of Sotera Health by 23.9% during the 2nd quarter. Vident Advisory LLC now owns 17,419 shares of the company’s stock worth $194,000 after acquiring an additional 3,364 shares during the last quarter. Tidal Investments LLC purchased a new position in Sotera Health during the 2nd quarter valued at $199,000. Boothbay Fund Management LLC purchased a new position in Sotera Health during the 2nd quarter valued at $210,000. Finally, Creative Planning boosted its holdings in Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after acquiring an additional 2,673 shares during the period. Institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.